Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mannose modified co-loaded antigen and double immuno-agonist phospholipid hybrid polymer vesicle as well as preparation method and application thereof

An agonist and polymer technology, applied in the field of biomedical engineering, can solve the problems of vaccines that cannot produce immune response strength, limit anti-tumor efficiency, etc., and achieve the effect of protecting the body from instability, optimizing the immune effect, and having a small particle size.

Active Publication Date: 2018-12-11
INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Peptide and protein vaccines targeting tumors are thought to activate CD4 + T and CD8 + T cells, but such vaccines cannot generate sufficient immune response strength thus limiting their antitumor efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mannose modified co-loaded antigen and double immuno-agonist phospholipid hybrid polymer vesicle as well as preparation method and application thereof
  • Mannose modified co-loaded antigen and double immuno-agonist phospholipid hybrid polymer vesicle as well as preparation method and application thereof
  • Mannose modified co-loaded antigen and double immuno-agonist phospholipid hybrid polymer vesicle as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0038] The present invention provides a method for preparing phospholipid hybrid polymer vesicles co-carrying antigens and dual immune agonists, comprising steps:

[0039] S1: Dissolve the amphiphilic triblock copolymer PCL-b-PEG-b-PCL and the immune stimulant in an organic solvent; Ultrasonic cell disruptor was used to sonicate for 5 minutes, and the antigen solution was dropped into the sonication process to obtain the primary emulsion;

[0040] Wherein, the mass ratio of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL and the immune stimulant is 20mg:2mg; the molecular weight of the amphiphilic triblock copolymer PCL-b-PEG-b-PCL It is 10000-24000, preferably 16000, wherein the mass percentage of PEG hydrophilic segment is greater than 45%; the amphiphilic triblock copolymer PCL-b-PEG-b-PCL is preferably PCL 4000 -PEG 8000 -PCL 4000 The immune stimulant is one or more of TLR4, TLR7 / 8, TLR1, TLR2, TLR5, TLR6, TLR3 and TLR9; preferably, the TLR7 / 8 agonist is IMQ and / or R...

Embodiment 1

[0052] This example provides a method for preparing phospholipid hybrid polymer vesicles co-loaded with antigens and dual immune agonists, including steps:

[0053] S1: 20 mg amphiphilic triblock copolymer PCL 4000 -PEG 8000 -PCL 4000 and 2mg of TLR7 / 8 agonist IMQ were dissolved in 1mL of dichloromethane; after fully dissolving, in an ice bath, ultrasonicated for 5min with a 3mm probe and an ultrasonic cell disruptor whose power was adjusted to 25% (16W). Inject 200 μL of 10 mg / mL OVA antigen solution to obtain a primary emulsion.

[0054] S2: Under the condition of magnetic stirring at 200rpm, drop the primary emulsion into 10mL of swollen polyvinyl alcohol (PVA) solution with a mass fraction of 2%, and the dropping time is 2min, then wash it with 1mL deionized water. Immediately, the cleaned mixture was ultrasonicated for 10 min with a 5mm probe and an ultrasonic cell disruptor with power adjusted to 30% (22W) in an ice bath to obtain a secondary emulsion.

[0055] S3: S...

Embodiment 2

[0059] This example provides a method for preparing phospholipid hybrid polymer vesicles co-loaded with mannose-targeted modified antigens and dual immune agonists, including steps:

[0060] S1: 20 mg amphiphilic triblock copolymer PCL 4000 -PEG 8000 -PCL 4000 and 2mg of TLR7 / 8 agonist IMQ were dissolved in 1mL of dichloromethane; after fully dissolved, under ice bath conditions, ultrasonic cell disruptor with 3mm probe and power adjusted to 25% (16W) was ultrasonicated for 5min. 200 μL of 10 mg / mL OVA antigen solution was added dropwise to obtain a primary emulsion.

[0061] S2: Under the condition of magnetic stirring at 200rpm, drop the primary emulsion into 10mL of swollen polyvinyl alcohol (PVA) solution with a mass fraction of 2%, and the dropping time is 2min, then wash it with 1mL deionized water. Immediately, the cleaned mixture was ultrasonicated for 10 min with a 5mm probe and an ultrasonic cell disruptor with power adjusted to 30% (22W) in an ice bath to obtain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a mannose modified co-loaded antigen and a double immuno-agonist phospholipid hybrid polymer vesicle as well as a preparation method and application thereof. A vaccine carriertakes an amphiphilic triblock copolymer as material, OVA is loaded in the hydrophilic inner cavity, IMQ is loaded in the hydrophobic membrane layer, DOTAP cationic layer is fitted with MPLA, and cationic lipid outer layer adsorbs outer layer OVA; phospholipid with reactive group is introduced to pass the targeted mannose ligand through covalently linked to the PEG-active distal end of the polymer-loaded vesicle surface, integrating the functions of active targeting of tumors, co-delivery of antigens and adjuvants and the like; the vesicle has the characteristics of small particle size, good dispersion, high antigen loading and good biocompatibility, etc., which can promote antigen uptake, DC activation and maturation, antigen cross-presentation, antigenic lymph node migration, lymphocyteactivation, effector T cell immune response, CD8<+> T and CD4<+> T cell responses, and memory T cells immune response.

Description

technical field [0001] The invention relates to the technical field of biomedical engineering, in particular to a mannose-modified co-loaded antigen and dual immune agonist phospholipid hybrid polymer vesicles and a preparation method and application thereof. Background technique [0002] Malignant tumors are currently a serious threat to human health, and the overall cure rate is less than 20%. The current clinical treatment methods for tumors mainly include surgical resection, chemotherapy and radiotherapy. These treatment methods often focus on local tumor lesions, and all of them have limitations. Surgical resection is ineffective for the treatment of metastatic tumors; chemotherapy and radiotherapy have severe side effects and seriously damage the patient's immune system. Tumor treatment has gone through traditional treatment to targeted therapy, and then to the latest cellular immunotherapy. Tumor immunotherapy has become the "fourth largest" tumor treatment method t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/69A61K47/60A61K47/26A61K47/22A61K47/42A61K39/12A61K39/00A61K39/015A61K39/10A61K39/29A61P31/04A61P31/20A61P35/00A61P33/06
CPCA61K39/0011A61K39/015A61K39/099A61K39/12A61K47/22A61K47/26A61K47/42A61K47/60A61K47/6915A61P31/04A61P31/20A61P33/06A61P35/00C12N2710/20034C12N2730/10134Y02A50/30
Inventor 张琳华朱敦皖胡春艳樊帆张志明
Owner INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com